Intended for licensed healthcare professionals located in the United Kingdom only.
FIGHT–202 was a multicentre, open-label, single-arm study to evaluate the efficacy and safety of PEMAZYRE in previously treated patients with locally advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA).1
The efficacy population consisted of 108 patients (105 patients with intrahepatic disease) whose disease had progressed after at least 1 prior therapy and who had fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement, as determined by the test performed at a central laboratory.1
Patients received PEMAZYRE in 21-day cycles consisting of 13.5 mg once-daily oral dosing for 14 days, followed by 7 days off therapy. PEMAZYRE was administered until disease progression or unacceptable toxicity.1
The major efficacy outcome measures were objective response rate (ORR) and duration of response (DOR), as determined by an independent review committee according to RECIST v1.1.1
(95% confidence interval [CI]:
Complete response = 3.7% (n=4)1
Partial response = 33.3% (n=36)1
Disease control rate (DCR)
(n=89; 95% CI: 73.9–89.1%)2
(95% CI: 5.65–13.14 months)a1
Patients with response
Median time to response1
(range, 0.7-6.9 months)1
a95% CI was calculated using the Brookmeyer and Crowley method.1
Best percentage change from baseline in target lesion size for individual patients with FGFR2 fusions or rearrangements3
Tumour response was assessed by independent review. Coloured bars indicate confirmed responses assessed by RECIST v1.1.
Dotted lines indicate the cutoff for partial response (–30%) and progressive disease (+20%).
*Patient had a decrease in target lesion size but was not evaluable for response using RECIST.
Figure reprinted from Abou-Alfa GK, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Lancet Oncol. 2020;21:671–84. Copyright © 2020 with permission from Elsevier Ltd. All rights reserved.
1. PEMAZYRE® (pemigatinib). Summary of Product Characteristics. 2021 (data cutoff: April 2020).
2. Incyte Data on File.
3. Abou-Alfa GK, et al. Lancet Oncol. 2020;21:671–84 (data cutoff: March 2019).